Drug Trial Radar · NCT06535893
Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 30, 2024
Primary completion
Jun 30, 2027
Study completion Jun 30, 2040
Sponsor
- Lead sponsor
- Nagoya City UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Japan Clinical Oncology Group
- First posted
- Aug 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.
Conditions
- Breast Cancer
Interventions
TNDrug
Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
TN-1Drug
Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
Primary outcomes
What the sponsor says the trial is designed to measure.
- pathological complete response (pCR)Time frame: Baseline to surgery
- ctDNA clearance rateTime frame: Before Neoadjuvant chemotherapy to surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nagoya City University
Nagoya, Aichi-ken, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.